Health · Pharma & Biotech · 2 days ago
Retatrutide, a New Weight-Loss Drug, Is Still in Clinical Testing
Retatrutide is an experimental medicine being developed by Eli Lilly for obesity and diabetes.
Like semaglutide and tirzepatide, it acts on hormone pathways linked to blood sugar and fullness, but it targets three receptors rather than one or two.
Early clinical findings suggest it may lead to greater weight loss than those medicines, while its effect on blood sugar appears similar.
Doctors cited in the story say its safety so far appears similar to other GLP-1 medicines, with stomach and digestive symptoms the most common side effects.
Retatrutide has not been approved by the US Food and Drug Administration and is still in phase 3 clinical testing.
That testing is the final step before the company can submit it to the FDA for review.
Some versions have appeared on gray markets before approval, but the story does not establish their safety.
Retatrutide is an experimental weight-loss drug nearing the end of phase 3 clinical testing.
The drug, developed by Eli Lilly, targets three hormone receptors: GLP-1, GIP and glucagon.
Doctors cited in Women's Health say it appears to have similar safety to other GLP-1 medicines so far, with gastrointestinal symptoms the most common adverse events.
Retatrutide has not been approved by the FDA.
The article says its main potential advantage over existing drugs is greater weight loss.
- Who
- Eli Lilly is developing retatrutide.
- What
- The experimental drug targets GLP-1, GIP and glucagon receptors and is being tested for diabetes and obesity care.
- When
- It is nearing the end of phase 3 testing.
- Where
- Not stated.
- Why
- It is being developed as a treatment for diabetes and obesity, with potential for greater weight loss than earlier drugs.
This story does not have two clearly opposing sides.
We call this the triple G agonist
In the leading clinical trials to date, gastrointestinal symptoms were the most common form of adverse events, as they are for other GLP-1 therapies
Eli Lilly's phase 3 testing compares retatrutide with existing medications such as semaglutide and tirzepatide.
Eli Lilly is nearing the end of phase 3, the final testing step before submitting the drug to the FDA for regulatory approval.
- Developer
- Eli Lilly
- Drug targets
- GLP-1, GIP and glucagon receptors
- Testing stage
- Nearing the end of phase 3
- Regulatory status
- Not approved by the FDA
- Trial location mentioned
- NYU Langone Health
Sources
Related news
Baby Sleep Gripe Water Recalled After Alcohol Found in Testing
FDA Warns Amazon Over Unapproved Herpes Treatments
Possible Wrong Dose Raises Questions for PDE9 Drug Trials in Heart Failure
Experimental eye drops improve vision in a small study of a rare eye disease
Brazil suspends Peptistrong supplement and orders all batches recalled
FDA approves atezolizumab with chemotherapy for some stage III colon cancers
Review links drug company gifts to more and less appropriate prescribing
Taboos limit sales of weight-loss drugs in India despite obesity rates
Roche reports year-long results for eye drug Vamikibart
Daily painkiller use can hide the cause of ongoing pain
Swiss oncologist warns US drug pricing pressure could delay cancer therapies
